Price$224.63-2.16 (-0.95%)
01:30 PM02:30 PM
News · 26 weeks124-68%
2025-12-142026-06-07
Mix6490d
- Other38(59%)
- Insider15(23%)
- SEC Filings7(11%)
- Earnings2(3%)
- Analyst2(3%)
Latest news
25 items- PRAbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026Data being presented, including six oral presentations, reinforce AbbVie's leadership and commitment to ongoing research to improve outcomes for people living with blood cancers NORTH CHICAGO, Ill., June 8, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will showcase clinical advancements from research programs across multiple blood cancers, including multiple myeloma (MM), follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), acute myeloid leukemia (AML) and amyloidosis (AL). Featured data from AbbVie's blood cancer portfolio and pipeline include 21 o
- PRAbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceNORTH CHICAGO, Ill., June 2, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. Management will participate in a fireside chat at 9:40 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key th
- SECSEC Form SD filed by AbbVie Inc.SD - AbbVie Inc. (0001551152) (Filer)
- PRAbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic LeukemiaAddition of VENCLYXTO plus acalabrutinib, with or without obinutuzumab, and VENCLYXTO plus ibrutinib supported by data from Phase 3 AMPLIFY trial, Phase 3 GLOW trial and Phase 2 CAPTIVATE trialFixed-duration VENCLYXTO-based combination regimens provide patients with additional CLL treatment options that may offer the potential for treatment-free intervals NORTH CHICAGO, Ill., May 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the European Commission (EC) has authorized an expanded label for VENCLYXTO® (venetoclax) to include use in combination with acalabrutinib (with or without obinutuzumab) and use in combination with ibrutinib for the treatment of adult patients with pre
- FDAFDA Approval for DECNUPAZ issued to ABBVIE INCSubmission status for ABBVIE INC's drug DECNUPAZ (ORIG-1) with active ingredient PIVEKIMAB SUNIRINE-PVZY has changed to 'Approval' on 05/27/2026. Application Category: BLA, Application Number: 761460, Application Classification:
- PRU.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options- DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient setting- DECNUPAZ marks AbbVie's first ADC approved for blood cancerNORTH CHICAGO, Ill., May 27, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and aggressive hematologic malignancy with limited treatment options. The approval is supported by data from the Phase 1/2 CADENZA trial, a global study evaluating the safety and efficacy of DECNUPAZ for BPDCN. "For patien
- SECSEC Form 144 filed by AbbVie Inc.144 - AbbVie Inc. (0001551152) (Subject)
- PRAbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C InfectionThe positive opinion is supported by data from the Phase 3 M20-350 study evaluating the safety and efficacy of MAVIRET® in adults with acute hepatitis C virus (HCV) infection.MAVIRET is a direct-acting antiviral (DAA) treatment currently approved in the European Union for chronic HCV infection in adults and children aged 3 years and older.Acute HCV infection is often asymptomatic, highlighting the importance of early diagnosis and treatment to help reduce transmission, long-term liver-related complications, and support HCV elimination efforts.NORTH CHICAGO, Ill., May 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Prod
- PRAbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline- Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline. The data will be shared through multiple oral presentations and posters spanning solid tumors and blood cancer indications. Collectively, these presentations highlight AbbVie's continued focus
- PRAllergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in AdultsBoey® has received a positive opinion from the CHMP for 30 EU & EEA markets If approved, Boey® has the potential to be the first and only botulinum neurotoxin serotype E that adult patients can try for the temporary improvement of Glabellar LinesPositive opinion is supported by data from two pivotal Phase 3 trials, which demonstrated rapid results as early as 8 hours and duration of 2-3 weeks2NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE:ABBV) and global leader in medical aesthetics, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending appro
- PRNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE:S
- PRCNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense ResearchAUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (BBB), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) are responding to this challenge with next-generation delivery pla
- SECAbbVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - AbbVie Inc. (0001551152) (Filer)
- INSIDERDirector Falk Thomas J was granted 1,118 shares, increasing direct ownership by 93% to 2,321 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Quaggin Susan E was granted 1,118 shares, increasing direct ownership by 44% to 3,643 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Rapp Edward J was granted 1,118 shares, increasing direct ownership by 2% to 45,964 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Meyer Melody B was granted 1,118 shares, increasing direct ownership by 7% to 17,616 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Freyman Thomas C was granted 1,118 shares, increasing direct ownership by 0.88% to 127,869 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Roberts Rebecca B was granted 1,118 shares, increasing direct ownership by 8% to 14,846 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Hart Brett J was granted 1,118 shares, increasing direct ownership by 6% to 20,590 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Davis Jennifer L. was granted 1,118 shares, increasing direct ownership by 44% to 3,643 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Waddell Frederick H was granted 1,118 shares, increasing direct ownership by 4% to 30,076 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Austin Roxanne S was granted 1,118 shares, increasing direct ownership by 3% to 39,576 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- INSIDERDirector Burnside William H.L. was granted 1,118 shares, increasing direct ownership by 4% to 28,076 units (SEC Form 4)4 - AbbVie Inc. (0001551152) (Issuer)
- SECSEC Form 10-Q filed by AbbVie Inc.10-Q - AbbVie Inc. (0001551152) (Filer)
ABBV FAQ
7 questionsWhat does AbbVie Inc. do?
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus...Where does ABBV stock trade?
AbbVie Inc. (ABBV) is listed on NYSE.What sector and industry is ABBV in?
AbbVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did AbbVie Inc. go public?
AbbVie Inc. (ABBV) completed its IPO in 2012.What are analysts saying about ABBV?
AbbVie Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-04-30.What companies are similar to ABBV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), NVS (Novartis AG), AMGN (Amgen Inc.), ABT (Abbott Laboratories). Compare ABBV side-by-side with any of them on Quantisnow.How can I track ABBV on Quantisnow?
Quantisnow aggregates AbbVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ABBV to receive live email and push alerts on every new disclosure.